The evolving future of PCSK9 inhibitors

RS Rosenson, RA Hegele, S Fazio… - Journal of the American …, 2018 - jacc.org
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …

[HTML][HTML] There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and …

ME Makover, MD Shapiro, PP Toth - American Journal of Preventive …, 2022 - Elsevier
Atherosclerotic cardiovascular disease (ASCVD) is epidemic throughout the world and is
etiologic for such acute cardiovascular events as myocardial infarction, ischemic stroke …

[HTML][HTML] Alterations in cholesterol metabolism as a risk factor for develo** Alzheimer's disease: Potential novel targets for treatment

R Loera-Valencia, J Goikolea… - The Journal of steroid …, 2019 - Elsevier
Alzheimer's disease (AD) is the most common form of dementia and it is characterized by the
deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain. However, the …

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic …

U Landmesser, MJ Chapman, JK Stock… - European heart …, 2018 - academic.oup.com
The first randomized controlled data from cardiovascular outcomes trials with proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. 1, 2 This …

Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care

GF Watts, SS Gidding, P Mata, J Pang… - Nature Reviews …, 2020 - nature.com
Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD

KN Hong, V Fuster, RS Rosenson, C Rosendorff… - Journal of the American …, 2017 - jacc.org
Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict
cardiovascular disease events. The effect of these risk factors on incident cardiovascular …

LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals

J Underberg, PP Toth, F Rodriguez - Postgraduate Medicine, 2022 - Taylor & Francis
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United
States. Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal risk factor for …